SCHEMBL8981850

SCHEMBL8981850

CNN(C)c1ccc(C)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
NPSR1 Q6W5P4 1/20 0.32
HPGDS O60760 1/20 0.32
KDM1A O60341 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2E1 P05181 1/20 0.31
CYP2A6 P11509 1/20 0.31
CYP2B6 P20813 1/20 0.31
CYP2C19 P33261 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
GAA P10253 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2304520 0.78 ALDH1A1 (0.48) ADRA2AADRA2BADRA2CKDM4ENPC1
SCHEMBL8981706 0.78 EDNRA (0.35) CYP1A2CYP2C19KDM4ENPC1L3MBTL1
SCHEMBL8980792 0.75 OXTR (0.44) KDM1ACYP2A6KDM4ENPC1RAB9A
SCHEMBL8981687 0.73 TRPV4 (0.46) KDM4EALDH1A1
SCHEMBL13942706 0.72 ALDH1A1 (0.45) NPSR1KDM4ENPC1RAB9AL3MBTL1
SCHEMBL8981848 0.72 MAPT (0.44)
SCHEMBL20037625 0.72 NOS1 (0.40) KDM1AKDM4E
SCHEMBL7662489 0.72 LMNA (0.53) HDAC1HDAC6ADRA2AADRA2BADRA2C
SCHEMBL13140620 0.71 ADRA2A (0.41) HDAC1HDAC6ADRA2AADRA2BADRA2C
SCHEMBL19121768 0.71 ADRA2A (0.33) HDAC1HDAC6ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD HDAC1 732/4885HDAC6 765/4885ADRA2A 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.